Malaria Vaccine Pioneer Wins the 2026 European Inventor Award
Sir Adrian Hill of Oxford’s Jenner Institute received the 2026 European Inventor Award for the R21/Matrix-M malaria vaccine, a low-cost shot with 75–80% efficacy now being rolled out across more than 20 African countries.
ScienceGNGV Editorial Team5 min read
One of the great public-health achievements of our era has just been honoured on the world stage. On July 3, 2026, at a ceremony in Berlin, the European Patent Office presented Sir Adrian Hill with the European Inventor Award in the research category for developing the R21/Matrix-M malaria vaccine, a shot that is already changing the odds for children across Africa.
Malaria remains one of humanity’s oldest and deadliest foes, killing hundreds of thousands of people every year, most of them young children. The R21/Matrix-M vaccine offers a powerful new line of defence, demonstrating roughly 75 to 80 percent protection in clinical trials, a level that meets and exceeds long-standing World Health Organization targets. Just as importantly, it was designed to be practical for the places that need it most: it costs less than €3 per dose and remains stable for up to two years under standard refrigeration. The WHO recommended it in 2023, Ghana and Nigeria were among the first countries to approve it, and it is now being folded into routine immunisation programmes in more than 20 African nations.
Hill, a Dublin-born scientist who studied medicine at Trinity College Dublin before earning a doctorate at Oxford, is director of the university’s Jenner Institute, where his team spent some three decades pursuing an effective malaria vaccine. His motivation was deeply personal. “I saw children dying from malaria right in front of me,” he recalled. “That experience stayed with me and convinced me that we needed something better than what was available.”
Hill is no stranger to vaccines that shape history; he also helped lead the team behind the Oxford–AstraZeneca COVID-19 vaccine and received an honorary knighthood in 2021. The 2026 award is a recognition not just of one inventor, but of the long, patient science that turns a stubborn hope into a real tool against one of the world’s cruellest diseases. For the millions of families living where malaria is a constant threat, that recognition carries the promise of healthier, safer childhoods.
Why it matters
The R21/Matrix-M vaccine offers roughly 75 to 80% protection against malaria, costs less than €3 a dose and stays stable under standard refrigeration. It is now part of routine immunisation in more than 20 African countries.
Sources
What you can do
Read the full story at The Irish Times, and learn about the malaria vaccine work of Oxford's Jenner Institute.
